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OBJECTIVES This study was designed to assess whether post-myocardial infarction (MI) in-scar trans-
plantation of skeletal myoblasts (SM) could reduce chronic ischemic mitral regurgitation
(MR) by decreasing left ventricular (LV) remodeling.
BACKGROUND Extensive work has confirmed the relationship between ischemic MR and post-myocardial
infarction (MI) remodeling of the LV.
METHODS An infero-posterior MI was created in 13 sheep, thereby resulting in increasing MR. Two
months post-MI, the animals were randomized and in-scar injected with expanded autolo-
gous SM (n 6, mean: 251 106 cells) or culture medium only (n 7). Three-dimensional
echocardiography was performed at baseline, before transplantation, and for two months
thereafter (sacrifice), with measurements of LV end-diastolic and end-systolic volumes
(ESV), ejection fraction (EF), MR stroke volume, and leaflet tethering distance; wall motion
score index (WMSi) was assessed by two-dimensional echo.
RESULTS Measurements were similar between groups at baseline and before transplantation. At
sacrifice, transplantation was found to have reduced MR progression (regurgitant volume
change: 1.83  0.32 ml vs. 5.9  0.7 ml in control group, p  0.0001) and tethering
distance (0.41  0.09 cm vs. 0.44  0.12 cm in control group, p  0.001), with significant
improvement of EF (2.01  0.94% vs. 4.86  2.23%, p  0.02), WMSi (0.25  0.11
vs. 0.13  0.03 in controls, p  0.01) and a trend to a lesser increase in ESV (23.3  3.5 ml
vs. 35.4  4.2 ml in control group, p  0.055).
CONCLUSIONS Autologous skeletal myoblast transplantation attenuates mild-to-moderate chronic ischemic
MR, which otherwise is progressive, by decreasing tethering distance and improving EF and
wall motion score, thereby enhancing valve coaptation. These data shed additional light on
the mechanism by which skeletal myoblast transplantation may be cardioprotective. (J Am
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.12.063Coll Cardiol 2006;47:2086–93) © 2006 by the American College of Cardiology Foundation
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dschemic mitral regurgitation (MR) is a common compli-
ation of ischemic heart disease that conveys an adverse
rognosis after both myocardial infarction (MI) and coro-
ary revascularization (1,2). Extensive work has confirmed
he relation of ischemic MR to remodeling and distortion of
he ischemic left ventricle (LV) (3–9). As viable myocardial
ells are lost, the wall becomes thinner and bulges outward,
process that begins almost immediately and then
rogresses over weeks to months (10). If the inferior wall of
he heart is involved, bulging of this wall also displaces the
ttached papillary muscles to which the mitral leaflets are
nchored. Displacement of these muscles tethers the leaflets
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005, accepted December 19, 2005.nto the ventricular cavity and restricts their ability to close
ffectively at the level of the annulus, where they insert. This
imits the surface over which the leaflets can make contact or
oapt, resulting in MR (11–15).
Ischemic MR is therefore an imbalance of the entire
itral-ventricular complex, including the LV wall. Accord-
ngly, reducing annular size alone, the standard therapeutic
pproach, is often ineffective because of persistent leaflet
ethering to the displaced papillary muscles (PMs) and LV
all (16–18). We have shown that this process can be
eversed by reshaping the heart surgically or with an external
atch. However, with these approaches, sizeable non-
ontracting segments of the muscle wall remain, which do
ot contribute to output (8,19).
After isolation from a skeletal muscle biopsy, skeletal myo-
lasts (SMs) have the capability to proliferate in culture, to
urvive in ischemic fibrosis, and to fuse into myotubes, forming
ong-term viable grafts (20–24). In animals, after injection in a
ost-infarction scar, autologous SM transplantation (treat-
ent) is effective to improve LV global and regional (within
he infarcted area) function, to limit LV remodeling and
ecrease LV end-systolic volume (ESV) (25,26).
We therefore proposed the hypothesis that skeletal myo-last transplantation has the potential to reduce leaflet
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May 16, 2006:2086–93 Ischemic MR and Cell Transplantationethering distance and ischemic MR by locally reshaping the
nfarcted wall and improving global LV function (Fig. 1).
his approach was tested in a chronic ischemic MR sheep
odel using three-dimensional (3D) and Doppler echocar-
iography to quantify MR and relate it to 3D changes in
alve configuration.
ETHODS
ll experiments were performed in accordance with the
Guiding Principles in the Care and Use of Animals” of the
merican Physiological Society.
hronic ischemic MR. We used the chronic ischemic MR
odel of Llaneras and Edmunds (27,28), which produces
R only with LV remodeling, eight weeks after ligating the
econd and third circumflex obtuse marginal coronary ar-
eries. Thirteen sheep (40 to 50 kg), anesthetized with
hiopentothal (0.5 ml/kg), intubated and ventilated at 15
Abbreviations and Acronyms
ESV  end-systolic volume
FBS  fetal bovine serum
IV  intravenously
LV  left ventricle
MHC  myosin heavy chain
MI  myocardial infarction
MR  mitral regurgitation
PM  papillary muscle
SM  skeletal myoblast
3D  three-dimensional
WMS  wall motion score
igure 1. Mechanistic hypothesis of the efficacy of skeletal myoblast tra
onfiguration of left ventricle (LV) with normal mitral leaflet closure. (Mi
ocal LV remodeling with outward bulging of the free wall, papillary mu
ransplantation reverses local remodeling with decreased tethering distance an
A  left atrium; MI  myocardial infarction; Post.  posterior.l/kg with 2% isofluorane and oxygen, and given glyco-
yrrolate (0.4 mg intravenously [IV]) and prophylactic
ancomycin (0.5 g IV), underwent sterile left thoracotomy,
ith procainamide (15 mg/kg IV) and lidocaine (3 mg/kg
V followed by 2 mg/min) given 10 min before coronary
igation. Sheep received oral amiodarone (400 mg daily)
or two days before infarction and oral acebutolol (200
g) and aspirin (250 mg) the day before infarction. After
aseline imaging, the pericardium was opened and the
econd and third circumflex obtuse marginal branches
ere ligated to infarct the infero-posterior wall. Imaging
as repeated and the thoracotomy closed (Fig. 2A).
ell transplantation. CELL CULTURES. At the time of
nfarction, a 10-mg skeletal muscle biopsy was obtained
rom the vastus lateralis. The biopsy was minced, frozen,
nd then cultured 14 days before transplantation (25). After
nzymatic dissociation, the tissue was centrifuged and the
emaining debris eliminated by filtration (100-m mesh).
ourteen days before transplantation, the cells were plated
nto Nunc substrates (103/cells/cm2) and grown in Ham
edium supplemented with fetal bovine serum (FBS) (20%,
erbio, Logan, Utah), beta-fibroblast growth factor (5 ng/ml,
igma, St. Louis, Missouri) and penicillin-streptomycin
10,000 IU/ml and 10 mg/ml, respectively, Gibco, Invitro-
en, Cergy Pontoise, France). Cells were expanded twice by
rypsinization before reaching confluence, and the culture
edium was then shifted to a differentiation medium
ontaining no beta-fibroblast growth factor and 2% FBS.
REPARATION OF CELLS. Fourteen days after plating, the
ells were harvested by trypsinization for implantation.
ntation on chronic ischemic mitral regurgitation (MR). (Left) Baseline
Chronic infero-posterior infarction: loss of viable myocardial cells induce
isplacement, and increased leaflet tethering and MR. (Right) Myoblastnspla
ddle)
scle dd improved leaflet coaptation and MR. Ao  aorta; Ant.  anterior;
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Ischemic MR and Cell Transplantation May 16, 2006:2086–93ollowing one rinse with Ca2- and Mg2-free phosphate-
uffered saline (Gibco, Invitrogen), the cells were incubated
or 5 min with trypsin-ethylene diamine tetra acetic. Upon
issociation, 10% (final volume) of FBS was added and the
ells were centrifuged (1,200 rpm). The cell pellet was
ashed three times in saline (NaCl 0.9%, Baxter) supple-
ented with bovine serum albumin (0.5%, Sigma). Cell
ounting was performed using the Neubauer hemacytome-
er, and a first assessment of cell viability was done using the
rypan blue dye exclusion technique. The cell pellet was then
esuspended in saline to a final concentration of 108 cells/
l. Aliquots were preserved for further characterization of
ell type and viability. Immediately before injection, cells
ere transferred to 1 ml syringes and warmed to room
emperature.
NTRAMYOCARDIAL INJECTIONS. Sheep were randomized
nto two groups receiving culture medium only (n  7,
ontrol group) or cells (n  6, myoblast group) in a
hysiologic salt solution with 0.5% bovine serum albumin.
ight weeks after infarction, during a repeat left lateral
horacotomy, 20 to 30 intramyocardial myoblast injections
ere performed across the bulging infero-posterior infarcted
rea (mostly underlying the posterior papillary muscle) using
27-gauge needle. Control sheep received an equivalent
olume of culture medium.
ssessment of results. CELL CHARACTERIZATION. At
igure 2. (A) Method. T0  Infarction and vastus lateralis biopsy; M2 
4  four months after infarction: sacrifice. At each time point three-dim
nalysis. 3D left ventricular volumes were obtained using endocardial bord
oints was established as reference frame; projecting the annulus onto this
losest leaflet-annulus approach), including papillary muscle-to-annulus tethach expansion time and at the final harvest, the cells were wnalyzed by flow cytofluorimetry for the CD56 myogenic
arker. The proportion of myogenic cells was evaluated
sing flow immunofluorescence as previously described (26).
ltrasonic assessment. ACQUISITIONS. After general an-
sthesia and during thoracotomy (for optimal imaging),
xaminations were performed: 1) at baseline; 2) immediately
efore injections (8 weeks after infarction, allowing MR to
evelop); and 3) 2 months after injections. Three-
imensional echo data were acquired with a 5-MHz epi-
ardial transducer (Philips Sonos 5500), scanning through a
ater bath from the LV apex using a rotating array with its
eam aligned through the center of the mitral valve, parallel
o the LV long axis (29,30). Onboard 3D software recorded
0 rotated images automatically at 6° increments, with
lectrocardiographic gating and suspended respiration. Dig-
tal images were transferred to a Silicon Graphics worksta-
ion (Fig. 2B).
The 3D echo analysis first established a reference frame,
he least-squares plane of the mitral annulus (29). Mitral
eometry was analyzed within this reference frame from
otated images at mid-systole, the time of closest leaflet-
nnulus approach. The mitral and aortic annuli were iden-
ified as the leaflet hinge points, confirmed by cineloop
eview. The PMs were traced and their most basal and
nterior tips identified by reviewing several adjacent images.
he tethering length over which the leaflets and chordae
months after infarction: time for MR to develop and time of injections;
nal (3D) and two-dimensional echo analysis were performed. (B) 3D echo
om nine views (left). The least-squares plane of the mitral annular hinge
gave annular area. Mitral geometry was analyzed at mid-systole (time of
distance (right). MImyocardial infarction; MRmitral regurgitation.two
ensio
ers frere stretched between the PMs and the relatively fixed
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May 16, 2006:2086–93 Ischemic MR and Cell Transplantationbrous portion of the annulus was then measured from
osterior PM tip to the medial trigone of the aortic valve
medial junction of aortic and mitral annuli) (Fig. 2B,
ight). Tethering length was used because in previous
tudies it has emerged as the strongest predictor of ischemic
R (6–8,13). These 3D echo measurements have been
hown to correlate well with those by sonomicrometer
rystal array, both in vitro and in vivo (r2 0.99, SEE 0.7
m, mean difference  0.08  0.7mm [NS vs. 0]) (6,8).
Two-dimensional epicardial echocardiography was per-
ormed for wall motion analysis scoring. One parasternal
V long-axis view was recorded, care being taken that the
itral and aortic valves and the apex were simultaneously
isualized, with three parasternal short-axis views recorded
t the base, PM, and apical levels. Acquisition of digital
ineloops and analysis of segmental wall motion and MR
troke volume were performed by a single experienced
perator blinded to the treatment group.
D LV VOLUME, MITRAL GEOMETRY, AND MR EVAL-
ATION. Three-dimensional LV volumes were obtained
sing endocardial border tracings from nine equally spaced
otated views (30). Mitral regurgitation stroke volume was
alculated as LV stroke volume minus aortic outflow volume
measured by pulsed Doppler). Regurgitant fraction was
alculated as (MR stroke volume)/(forward aortic  MR
troke volumes). Mitral annular area was calculated by
rojecting the mitral annular hinge points onto the least-
quares reference plane. Mitral geometry was analyzed at
id-systole (time of closest leaflet-annulus approach), in-
luding the PM-to-annulus tethering distance previously
escribed (6,8,13,15).
CORING OF REGIONAL CONTRACTILITY. Using the three
hort-axis views, the LV was divided into 16 segments accord-
ng to American Society of Echocardiography recommenda-
ions, and a score was allocated to each segment according to
ts contractility as (0) normokinetic, (1) hypokinetic, (2)
kinetic, or (3) dyskinetic. A global wall motion score
able 1. Echocardiographic Measurements
Baseline
Control
Cell
Transplantation C
R 99.5  1.6 99.1  2.7 103
DV(ml) 32.01  0.5 32.2  1.6 63
SV(ml) 10.5  0.33 11.8  0.5 39
F 0.67  0.01 0.63  0.02 .3
MS indexed 0.0  0.0 0.0  0.0 1.2
ethering dist (cm) 2.48  0.03 2.5  0.05 3.0
AA (cm2) 5.8  0.04 5.8  0.19 6
RSV (ml) 1.14  0.2 1.33  0.41 7
F% 5.4  0.9 6.3  1.8 3
ll two-way ANOVAs but one (heart rate) were significant p 0.05. Significant chan
s. chronic MI, †chronic MI vs. sacrifice.
EDV  left ventricular end-diastolic volume; EF  ejection fraction; ESV  le
yocardial infraction; MRSV  mitral regurgitation stroke volume; RF  regurgit
apillary tips and anterior mitral annulus; WMS  wall motion score.WMS) was derived from the algebraic sum of these values, mnd the WMS index was then obtained by dividing WMS by
he total number of scored segments (n  16) (31).
athologic assessment. Sacrifice was performed after the
ast ultrasonic evaluation, and the hearts were explanted
nd rinsed in a saline buffer. Location and extent of MI
ere visually assessed. The entire portion of the LV
ontaining the MI was fixed in formalin for histology and
mmunohistochemistry.
ISTOLOGIC STUDIES. Formalin-fixed paraffin-embedded
ections of the whole MI were stained with hematoxylin-
osin-safranin for qualitative assessment of scar and grafted
ells focusing on fibrosis, fat tissue, inflammation, and
yocyte necrosis; and presence, density, organization and
ifferentiation of grafted cells.
MMUNOHISTOCHEMICAL STUDIES. On selected paraffin
ections, immunohistochemistry for skeletal fast isoform
MY-32 clone monoclonal antibodies (Sigma) and cardiac
nd skeletal slow isoforms (NOQ7 clone monoclonal anti-
odies (Sigma) of myosin heavy chain (MHC) was per-
ormed as previously described (25).
tatistical analysis. Echocardiographic measurements
ere compared among stages and sheep by repeated-
easures ANOVA. Significant ANOVAs were explored
y two paired t tests (chronic ischemia vs. baseline and
s. sacrifice), with significance at p  0.025 (Bonferroni-
orrected). Differences in progression between the two
roups were explored by unpaired t test, with significance at
 0.05. All data were reported as means  SEM.
tatistical analysis used StatView 5.0. Reproducibility of
chographic measurements was tested by two independent
bservers and gave a variability of 2.5% of the mean.
ESULTS
yocardial infarction was created in 13 animals: 7 controls
nd 6 given myoblasts. All animals remained available for
chocardiography at two months after infarction (pretreat-
Chronic MI Sacrifice
ol
Cell
Transplantation Control
Cell
Transplantation
.4 100.6  3.6 109.7  2.9 100.8  4.9
.1* 62.6  5.1* 111.0  3.8† 102.3  5.1†
.7* 39.7  3.1* 75.4  4.1† 63  2.9†
.02* .36  0.02* .33  0.01 .38  0.01
.08* 1.19  0.05* 1.39  0.11† .94  0.13†
.05* 2.9  0.06* 3.5  1.1† 2.51  0.04†
.19* 6.3  0.12* 7.2  0.12† 6.6  0.18†
.59* 5.8  0.59* 13.1  0.77† 4  0.51†
.5* 27.4  4.8* 36  1 10.5  1.6†
 0.025 (Bonferroni-corrected) are indicated for the two-way comparisons: *Baseline
ricular end-systolic volume; HR  heart rate; MAA  mitral annulus area; MI 
fraction; Tethering dist  three-dimensional tethering distance between posteriorontr
.1  3
.4  3
.1  1
8  0
5  0
7  0
.8  0
.2  0
0  0
ges p
ft ventent) and at time of sacrifice (4 months post-MI). Param-
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Ischemic MR and Cell Transplantation May 16, 2006:2086–93ters were similar between groups at baseline and at 2
onths (pretreatment) (Table 1, columns 1 and 2).
ell cultures. Cultures yielded to 251  42 million cells
170 to 150 million) with 60  2.7% (50% to 70%)
yogenic cells.
D ultrasonic functional assessment and evaluation of
R. PROGRESSION OF ISCHEMIC MR. At the time of acute
nfarction, LV dilation was limited and, as at baseline, the
eaflets closed at the annular level with only trace MR. At
wo months post-MI, LV volume was comparable between
roups (30.4 5.6 ml in treatment group vs.31.4 3.5
l in control group for end-diastolic volume, p  0.32; and
28.1  5.9 ml in treatment group vs. 28.56  2.09 ml
n control group for end-systolic volume, p  0.31). With
ulging of the affected wall, the leaflets were apically tented
ith mild-to-moderate MR (regurgitant fraction: 27.4 
.8% vs. 30  5% in the treatment and control groups,
espectively; p  0.51). Papillary muscle tip displacement
way from the annulus was comparable between groups (2.9
.06 cm vs. 3.07  0.05 cm, p  0.87) (Table 1, Fig. 3).
EVERSAL OF ISCHEMIC MR. Two months after myoblast
reatment (i.e., 4 months post-infarction), there was a
eduction in ischemic MR (5.8  0.59 ml/beat before
reatment vs. 4.0  0.51 ml/beat 2 months after treatment,
 0.01) and in MR progression (regurgitant volume:
igure 3. Mid-systolic apical two-dimensional echo images. (Left) Mild b
o the annulus (dashes) in the direction of tethering (upward arrows). Mi
ell transplantation restores a more normal LV shape with less bulging of the in
mproved coaptation and no MR (bottom panel) despite important LV dilatio1.83  0.32 ml/beat vs. 5.9  0.7 ml/beat in the treatment
nd control groups, respectively, p  0.0001) (Figs. 3 and
A), with a reduction of tethering distance (2.9  0.06 cm
retreatment vs. 2.51  0.04 cm 2 months after treatment
n the treated group, p  0.01) and in its progression
0.41  0.09 cm vs. 0.44  0.12 cm in the treatment and
ontrol groups, respectively, p  0.001) (Fig. 4B). This
aralleled a significant improvement of the left ventricular
jection fraction (2.01  0.94% in treatment group vs.
4.86  2.23% in control group, p  0.02) (Fig. 5A) and
MS index (0.25  0.11 in treatment group vs. 0.13 
.03 in control group, p  0.01) (Fig. 5B). The benefits of
yoblast treatment were also suggested by a trend (almost
ignificant) to a lesser increase in global ESV (23.3 3.5 ml
n the treatment group vs. 35.4  4.2 ml in control group,
 0.055). Mitral annular area increased eight weeks
ost-MI in parallel with development of MR, but its
rogression did not decrease significantly after treatment
Table 1).
athologic assessment. Scar sizes were similar between
he two groups and always extended to the posterolateral
V wall and the posteromedial papillary muscle. In control
ubjects, scars were always transmural, with fibrous tissue
ntermingled with fat tissue (Fig. 6A). In the majority (5 of
) of transplanted animals, large areas of grafted cells were
g of the infarcted infero-posterior wall with apical leaflet tenting relative
moderate MR in the more globular remodeled LV is seen below. (Right)ulgin
ld-to-fero-posterior wall (upward arrows) and decreases tethering distance with
n. Abbreviations as in Figure 1.
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May 16, 2006:2086–93 Ischemic MR and Cell Transplantationound within the scars (Fig. 6B). These cells displayed
ypical histologic features of well-differentiated skeletal
yotubes (Fig. 7A) and often had a tendency to organize in
arallel (Fig. 7B). In all transplanted animals, antibodies
irected against the fast MHC isoform identified the
resence of skeletal muscle structures surrounded by fibrotic
nd residual cardiac tissue, which was not labeled (Fig. 7C).
rafted myocytes maintained their skeletal myocyte differ-
ntiation and were all negative for the slow MHC isoform
Fig. 7D).
ISCUSSION
schemic MR is principally caused by LV remodeling with
utward PM displacement and increased tethering (4–16).
he current study assessed whether chronic ischemic MR
an be reduced using autologous skeletal muscle transplan-
ation within the infarcted area at a chronic stage (20–23).
Skeletal myoblasts are precursor cells located under the
asal lamina of the adult skeletal muscle and committed to
ultiply after injury (32). They possess a high potential for
ivision in culture and further multiplication after intramyo-
ardial grafting (33).
Our hypothesis was that myoblast transplantation can
educe ischemic MR through a decrease in localized LV
all deformation and bulging. In the chronic post-MI
etting, such a procedure has been effective experimentally
n improving global and regional LV systolic function and
imiting LV remodeling (25,26). In the current study,
yoblast transplantation successfully decreased chronic
ild-to-moderate ischemic MR (that was otherwise pro-
ressive) by significantly decreasing leaflet tethering dis-
igure 4. Efficacy of myoblast transplantation. Parallel variations in mitral
egurgitation (MR) stroke volume (A) and tethering distance (B). MI 
yocardial infarction.ance, consistent with infarct zone reshaping, and reposi-
f
iioning the PM closer to the annulus. This can be
nderstood based on the known dependence of ischemic
R on localized LV remodeling and the central and
redominant role of tethering as the final common pathway
n inducing ischemic MR, independent of global LV size
nd function (6,10,11,13). The decrease in tethering length
s consistent with the engraftment of myotubes within the
nfarcted wall and the potential cell-mediated changes in
xtracellular matrix (34). This mechanistic hypothesis actu-
lly fits with previous experiments in which small displace-
ents of the PM tip created large, nonlinear changes in MR
6,8,9). The mild reduction in abnormal wall motion score
ay reflect limitation of remodeling and outward infarct
ulging by new cell growth. This limitation of LV remod-
ling could explain the significantly lower EF deterioration
n the cell group, and the lower ESV increases (25,26). It is
eyond the scope of this study to determine whether
yoblast transplantation may also provide benefits other
han limitation of remodeling, which might include con-
raction of engrafted myotubes fused with host cardiomyo-
ytes or paracrine mobilization of cardiac stem cells (35,36).
tudy limitations and future directions. The scope of this
tudy is sharply focused on the problem of inferoposterior
I, a common cause of ischemic MR. In case of global LV
ysfunction, the major determinant of MR remains the
isplacement of the PMs, which are located in the posterior
ortion of the LV. Therefore, a similar approach could in
rinciple achieve a beneficial effect by injecting skeletal
yoblasts around both PM regions (6). Finally, these
ositive results could justify further studies using percuta-
eous techniques of myoblast delivery, particularly through
he coronary veins (37).
igure 5. Effects of myoblast transplantation on left ventricular ejection
raction function (A) and wall motion score (WMS) (B). MI myocardial
nfarction.
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Ischemic MR and Cell Transplantation May 16, 2006:2086–93onclusions. In the chronic post-infarction setting, autol-
gous skeletal myoblast transplantation attenuates mild-to-
oderate chronic ischemic MR, which is otherwise progres-
ive, by decreasing tethering distance over which the leaflets
re stretched and improving ejection fraction and wall
igure 6. Histology of the subpapillary muscle region. (A) Chronic infarct
H&E stain, bar 600 m). (B) Scar area in a grafted sheep at two months
ells (black arrow) replacing fat and fibrous tissues (H&E stain, bar  6
igure 7. Organized skeletal muscle cells. Treated area in a grafted sheep
raversal section and surrounded by fibrous tissue (H&E stain; bar  100
eripheral nuclei (*) and abundant myofilaments (H&E stain; bar  150 
mmunostaining for the fast isoform of the beta myosin heavy chain (My 32; bar
f beta myosin heavy chain (NOQ7; bar  200 m).otion score, thereby enhancing valve coaptation. Given
he limitations of existing methods for repairing ischemic
R in patients (38), it is conceivable that such a procedure
ay be considered as a complement to standard surgical
herapy in the future.
fter four months) in a control animal characterized by dense fibrous tissue
transplantation with identification of a group of well-differentiated grafted
).
months after transplantation. (A) (40) High density of grafted cells on
. (B) (300) Skeletal myotubes (SM) organized in parallel with multiple
(C) Section of an engrafted scar area at two months after transplantation.ion (aat two
m)
m). 200 m). (D) To a serial section, immunostaining for the slow isoform
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